Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Editas Medicine
(NQ:
EDIT
)
5.320
-0.310 (-5.51%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Editas Medicine
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Is Editas Stock a Buy Now?
October 07, 2023
Shares of the gene-editing company are close to their 52-week lows. Does it make sense to buy the stock now?
Via
The Motley Fool
Avoid Big Losses With Biotech Stocks by Paying Attention to These 2 Things
October 05, 2023
It's key to understand the resources it will take to deliver a company's pipeline.
Via
The Motley Fool
Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics
October 02, 2023
The better of the pair should be able to beat Bluebird Bio.
Via
The Motley Fool
Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
September 29, 2023
Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group for $13 per share.
Via
Benzinga
Expert Ratings for Editas Medicine
September 29, 2023
Via
Benzinga
Editas Medicine Inc. (NASDAQ: EDIT) Near the Top of Equities by Percentage Gain on 9/29
September 29, 2023
Via
Investor Brand Network
Analyst Expectations for Editas Medicine's Future
August 29, 2023
Via
Benzinga
Editas Medicine Is Beyond Skepticism, Analyst Has Confidence In Sickle Cell Therapy, Upgrades Stock
September 29, 2023
Stifel has upgraded Editas Medicine Inc (NASDAQ: EDIT), saying the company's sickle cell disease candidate, EDIT-301's progress, has received minimal credit from investors.
Via
Benzinga
Why Editas Medicine Stock Is Soaring Today
September 29, 2023
Investors are cheering a big analyst upgrade for the gene-editing stock.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023
September 29, 2023
Via
Benzinga
Expert Ratings for Editas Medicine
August 03, 2023
Via
Benzinga
Is Editas Medicine Stock a Buy Now?
June 28, 2023
The fortunes of this once-promising biotech company have changed in the past year.
Via
The Motley Fool
Nike To Rally Around 53%? Here Are 10 Other Analyst Forecasts For Friday
September 29, 2023
Piper Sandler cut the price target for Accenture plc (NYSE: ACN) from $312 to $300. Piper Sandler analyst Arvind Ramnani maintained a Neutral rating. Accenture shares rose 0.3% to $301.56 in pre-market...
Via
Benzinga
Nike, OPKO Health And Other Big Stocks Moving Higher In Friday's Pre-Market Session
September 29, 2023
U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording gains in today’s pre-market trading session.
Via
Benzinga
Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer
September 25, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session
September 25, 2023
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138.
Via
Benzinga
Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer
September 25, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Are Gene Therapy Stocks The Market's Next Big Winners?
September 25, 2023
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
1 Gene Editing Stock to Buy Now, and 1 to Sell
September 23, 2023
Target markets matter. So does having the cash to get to them.
Via
The Motley Fool
Editas Medicine Announces Upcoming Investor Events
August 30, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street
August 23, 2023
Is the Street's optimism justified here?
Via
The Motley Fool
Editas Medicine Announces Second Quarter 2023 Results and Business Updates
August 02, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas’ Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization
July 27, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update
July 26, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer
July 24, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
This 1 Problem Could Sink at Least 4 Gene-Editing Stocks
June 29, 2023
Reaching profitability could be harder than investors expect.
Via
The Motley Fool
What Is CRISPR And Why Should Your Portfolio Care?
June 25, 2023
CRISPR Therapeutics continues to be at the forefront of CRISPR-based therapeutics development. It's the first, and largest, but not the only player.
Via
Talk Markets
After It Fell 15% in 1 Day, Should You Buy The Dip on Editas Stock?
June 20, 2023
It's not about to start making money anytime soon.
Via
The Motley Fool
Why John Wiley & Sons Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
June 15, 2023
Gainers SCWorx Corp. (NASDAQ: WORX) shares jumped 281% to $0.8396.
Via
Benzinga
2 Short-Squeeze Candidates That Could Go Parabolic
June 15, 2023
Editas Medicine and Bluebird Bio have been favorite targets for short-sellers lately.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.